
Alnylam (ALNY) Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has approved Livsayis, an Alnylam-discovered RNAi therapeutic that was developed and will be commercialized by Regeneron, for the
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| ALNY | Alnylam Pharma | 147.82 | -297.97 | -66.84% |
| Name | Price | % Change | |
|---|---|---|---|
| $147.82 | -66.84% |

Alnylam (ALNY) Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has approved Livsayis, an Alnylam-discovered RNAi therapeutic that was developed and will be commercialized by Regeneron, for the

JPMorgan lowered the firm’s price target on Alnylam (ALNY) to $254 from $369 and keeps an Overweight rating on the shares. The firm attributes the stock’s 61% selloff year-to-date on

Cantor Fitzgerald lowered the firm’s price target on Alnylam (ALNY) to $205 from $290 and keeps a Neutral rating on the shares. Alnylam has lost over $30B in market value

H.C. Wainwright lowered the firm’s price target on Alnylam (ALNY) to $250 from $455 and keeps a Buy rating on the shares. The firm cites Ssower Amvuttra starts and tighter

Oppenheimer initiated coverage of City Therapeutics (CTY) with an Outperform rating and $46 price target. The company, which is developing siRNA medicines, was co-founded by Alnylam’s (ALNY) founding CEO, who

Alnylam Pharmaceuticals (ALNY) announced that its collaborator, Regeneron Pharmaceuticals (REGN), shared initial results from a first-in-human trial that demonstrated a single subcutaneous dose of CIDEBsiRNA rapidly normalized liver fat and

Alnylam (ALNY) Pharmaceuticals announced new data at the American Heart Association Scientific Sessions 2026. The analyses, including data from the HELIOS-B Phase 3 two-year open-label extension period, show that patients

Citi lowered the firm’s price target on Alnylam (ALNY) to $250 from $320 and keeps a Buy rating on the shares. The firm cites reset of Amvuttra’s net price for

Bank of America Securities analyst Tazeen Ahmad has maintained their bullish stance on ALNY stock, giving a Buy rating today. Tazeen Ahmad’s rating is based on several factors, including Alnylam’s

Alnylam Pharma ( ($ALNY) ) has shared an update. On November 4, 2026, Alnylam Pharmaceuticals announced that Executive Vice President and Chief Commercialization Officer Tolga Tanguler would depart in December
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 18, 2026 | ||||
| buy | Reiterated | Nov 17, 2026 | ||||
| hold | Assigned | Nov 17, 2026 | ||||
| buy | Reiterated | Nov 10, 2026 | ||||
| buy | Reiterated | Nov 10, 2026 | ||||
| buy | Assigned | Nov 5, 2026 | ||||
| buy | Reiterated | Nov 5, 2026 | ||||
| buy | Reiterated | Nov 5, 2026 | ||||
| hold | Reiterated | Nov 4, 2026 | ||||
| hold | Downgraded | Nov 2, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 18, 2027TBA | $20.01B | $1.72 | $1.52B | -0.79 | 7.33 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.